Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Spinraza, Zolgensma, and Evrysdi are all used to treat SMA. Spinraza and Evrysdi are used in adults and children of any age, while Zolgensma is used only in children younger than 2 years old.

Spinraza, also known as nusinersen, is a medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a genetic disease that is passed down through families. It leads to ...

Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates ...

Spinraza (nusinersen) is a brand-name drug that’s prescribed for spinal muscular atrophy (SMA) in adults and children. Spinraza comes as a spinal injection that’s given by a healthcare ...

Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adults The longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ...

Many SMA patients continue to see gains in motor function with long-term Spinraza treatment, a real-world study from ...

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

In 2016, Spinraza® became the first FDA-approved treatment for spinal muscular atrophy. ... Over 11,000 SMA patients have been treated with Spinraza® in more than 50 countries.

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise. Its latest ...

Biogen Inc BIIB announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA. RESPOND is an ongoing two-year, phase 4 open-label ...